<DOC>
	<DOCNO>NCT00534677</DOCNO>
	<brief_summary>Terlipressin Octreotide two common agent use adjuvant management variceal bleeding . Both agent claim equivalent endoscopic therapy randomize study . There head head clinical trial two agent available literature . We aim compare efficacy safety Terlipressin Octreotide combination Endoscopic Variceal band Ligation ( EVL ) patient present Esophageal Variceal Bleed ( EVB ) .</brief_summary>
	<brief_title>The Safety &amp; Efficacy Terlipressin v Octreotide Control Variceal Bleed</brief_title>
	<detailed_description>The effectiveness combine Endoscopic treatment Octreotide Terlipressin prospectively study esophageal variceal hemorrhage ( EVH ) . This prospective , randomized clinical trial help u well patient management efficiently cost effectively .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Hematemesis</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Terlipressin</mesh_term>
	<mesh_term>Lypressin</mesh_term>
	<criteria>All cirrhotic patient upper GI bleed secondary esophageal varix 18 year age Ulcerative esophagitis , Mallory Weiss tear , Bleeding gastric duodenal ulcer , Bleeding gastric varix portal hypertensive gastropathy Upper GI bleed result thrombocytopenia bleed diathesis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Variceal bleed</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Vasoactive agent</keyword>
	<keyword>Terlipressin</keyword>
	<keyword>Octreotide</keyword>
	<keyword>Safety &amp; Efficacy</keyword>
</DOC>